Chapter 5: Management of cystic fibrosis-related diabetes
Moderator(s): Forum Admin, David Maahs
Page 1 of 1
Thread Actions

1/24/2018 at 3:59:08 PM GMT
Posts: 19
Chapter 5: Management of cystic fibrosis-related diabetes

Dear ISPAD member/friend,

Thank you for your continued interest in the 2018 ISPAD Clinical Practice Consensus Guidelines and in the previous drafts chapters we shared with you.

We are happy to announce that Chapter 5 on the Management of cystic fibrosis-related diabetes is now ready for you to read and comment on. We are looking forward to hearing your thoughts and input on this chapter. 

Kind regards,

David Maahs

ISPAD Secretary-General


 Attached Files: 

Last edited Wednesday, January 24, 2018
1/26/2018 at 4:42:29 PM GMT
Posts: 3
There is a study comparing insulin Treatment with Repaglinide at the beginning of CFRD (Lancet Diabetes Endocrinol. 2017 Nov 30. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial.
Ballmann M1, Hubert D2, Assael BM3, Staab D4, Hebestreit A5, Naehrlich L6, Nickolay T7, Prinz N8, Holl RW8; CFRD Study Group.) This study should urgently be added because it shows some evidence for oral antidiabetic treatement especiallay at the beginning of the disease.
There are some limitations in this Trial (high drop Outs in the repaglinide arm) however the Trial should be added to the refernces and be carefully discussed in the Guidelines.


Contact Us

ISPAD Executive Office
c/o K.I.T. Group GmbH
Association & Conference Management
Kurfürstendamm 71
10709 Berlin, Germany










Join ISPAD

Click the link below to join the Society!


Join Today!










Phone: +49 (0)30 24603-210
Fax: +49 (0)30 24603-200
Email: secretariat@ispad.or
g










Privacy Policy
Terms of Service
Legal Notice    

Disclaimer



































 © 2017 International Society for Pediatric and Adolescent Diabetes (ISPAD)






Association Management Software Powered by YourMembership  ::  Legal